ClinicalTrials.gg
Active, not recruitingNCT04196972Updated Oct 6, 2026

Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

An interventional study of Communication Intervention and Questionnaire Administration in Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center — 21 open to participants now, 42 under way, 1 of them phase 3. Hematologic Neoplasms · M.D. Anderson Cancer Center.

Enrollment
36th of 69
36 · median 40
Started
2020
with 23 others
No phase
10 of 99
2 open now
Primary completion
2026-12
later than 5 of 41 live
Registered
50th of 99
by date

Among the 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center, this one is the 36th largest by enrollment of the 69 interventional ones that give a count, is one of 24 that started in 2020, is one of 10 with no phase, reaches primary completion later than 5 of the 41 other live ones, and was the 50th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

21 of the 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This trial studies how well the Extension for Community Healthcare Outcomes (ECHO) telementoring intervention works in transforming professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians. This study may help researchers learn more about the potential benefits of a model for team meetings aimed at bringing physicians together from multiple practice locations when few opportunities exist for meaningful, collegial interactions. It may also help diagnostic imaging clinicians engage more effectively with colleagues at distant sites and become more engaged with their work.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the feasibility of the proposed anti-burnout intervention for faculty at MD Anderson, defined as at least 35/50 of participants each attending at least 9 out of 13 sessions.

SECONDARY OBJECTIVES:

I. To explore any changes in burnout, measured by the Maslach Burnout Inventory (MBI) and Mini-Z surveys.

II. To explore any changes in the self-reported health status of participants, as measured by the RAND Short-Form 36 (SF36) survey.

III. To understand participants' perception of the benefits and usefulness of the intervention, measured by the customized Globalized Perception/Impression of Benefits Survey.

IV. To define methods for improving the intervention, based on participants' feedback following each session.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM A: Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

ARM B: Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

03

Conditions studied

  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Faculty must be diagnostic imaging clinicians with a primary appointment in the Division of Diagnostic Imaging at MD Anderson

Exclusion criteria

Exclusion Criteria:

  • Faculty that have an official leadership role (Division Head or Department Chair)
  • Faculty that have previously participated in any previous live ECHO clinic or ECHO activity
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm A (ECHO telementoring)

    Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

    Other: Communication Intervention · Other: Questionnaire Administration

  • Experimental
    Arm B (wait-list, ECHO telementoring)

    Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

    Other: Communication Intervention · Other: Questionnaire Administration · Other: Waiting List

Interventions

  • OtherCommunication Intervention

    Receive ECHO telementoring intervention

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherWaiting List

    Placed on wait-list

    Also known as: Waitlist

06

What researchers measure

Primary outcomes

  1. Proportion of sessions attended

    Will be evaluated by attendance records for each session. Will estimate the attendance rate (p = proportion of participants attending at least 9 out of 13 sessions) with 95% confidence intervals.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 76 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 12, 2019
StartActual
Aug 16, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04196972
Responsible party
Sponsor
First posted
Dec 12, 2019
Start date
Aug 16, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Eduardo Bruera
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion